Nifuroxazide

Chemical properties

Yellow Solid

Originator

Ercefuryl,Carriere,France,1964

The Uses of Nifuroxazide

Nifuroxazide is an intestinal antiseptic. Nifuroxazide, is still used as a veterinary drug illegally in some countries. SEE H829102 as a test for antibiotic in broiler chickens.

What are the applications of Application

Nifuroxazide is an inhibitor of STAT activation and signaling activity

Definition

Nifuroxazide is a member of benzoic acids. Nifuroxazide is an oral nitrofuran antibiotic used to treat mild diarrhea in humans and animals.

Manufacturing Process

13 g (0.1 mol) of 4-hydroxybenzhydrazide were dissolved in a boiling mixture of 100 ml of water and an equal volume of dimethylformamide. 15.5 g (0.11 mol) of 5-nitrofurfural dissolved in 31 ml of dimethylformamide were added to this hot solution, and the mixture was stirred and brought to the boiling point.
The mixture was then allowed to stand for fifteen hours. The precipitate was separated, washed twice with 100 ml of water, and recrystallized by dissolving it in 250 ml of hot pyridine and pouring this solution into 250 ml of water.
The 5-nitrofurfurylidene hydrazide of 4-hydroxybenzoic acid obtained was washed with water and methanol and was dried at a moderate temperature. It weighed 23 g (83.7% yield), and melted at 298°C. The percentage nitrogen determined by the micro-Dumas method was 15.41% (theory 15.27%).

Therapeutic Function

Antiseptic

Biological Activity

Nifuroxazide is a nitrofuran antibiotic. It is active against strains of the enteropathogenic bacteria C. jejuni, Salmonella, Y. enterocolitica, Shigella, and E. coli. It inhibits quorum sensing and virulence factor production in P. aeruginosa. Nifuroxazide inhibits STAT3 activity in a reporter assay (IC50 = ~3 μM) and decreases viability of U266 and INA-6 myeloma cells, which have constitutive STAT3 phosphorylation, with EC50 values of approximately 4.5 μM for both. It also decreases viability, migration, and invasion of, and induces apoptosis in, MCF-7, 4T1, and MDA-MB-231 breast cancer cells. Nifuroxazide (50 mg/kg per day) reduces tumor growth and prevents pulmonary metastasis in a 4T1 murine mammary carcinoma model. It also reduces diarrhea, weight loss, and colon inflammation in a rat model of acetic acid-induced ulcerative colitis.